A Phase 2 Study of Seviteronel (INO-464) in Patients with Metastatic Castration-Resistant Prostate Cancer Post-Enzalutamide Treatment

BACKGROUND: Seviteronel was being developed by Innocrin Pharamceuticals as a selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) inhibitor and androgen receptor (AR) antagonist with activity against prostate cancer cells in vitro and in vivo. This open-label Phase II clinical study evaluated t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Genitourin Cancer
Main Authors: Madan, Ravi A., Schmidt, Keith T., Karzai, Fatima, Peer, Cody J., Cordes, Lisa M., Chau, Cindy H., Steinberg, Seth M., Owens, Helen, Eisner, Joel, Moore, William R., Dahut, William L., Gulley, James L., Figg, William D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7415516/
https://ncbi.nlm.nih.gov/pubmed/32327394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2019.11.002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados